181 related articles for article (PubMed ID: 35988810)
1. Genotoxicity evaluation of a valsartan-related complex N-nitroso-impurity.
Glowienke S; Onken U; Elhajouji A; Muthusamy S; Sangana R; Martus HJ; Bedman T; Hartmann A
Regul Toxicol Pharmacol; 2022 Oct; 134():105245. PubMed ID: 35988810
[TBL] [Abstract][Full Text] [Related]
2. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
[TBL] [Abstract][Full Text] [Related]
3. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
4. A deep dive into historical Ames study data for N-nitrosamine compounds.
Tennant RE; Ponting DJ; Thresher A
Regul Toxicol Pharmacol; 2023 Sep; 143():105460. PubMed ID: 37495012
[TBL] [Abstract][Full Text] [Related]
5. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
[TBL] [Abstract][Full Text] [Related]
6. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
Charoo NA; Ali AA; Buha SK; Rahman Z
AAPS PharmSciTech; 2019 Apr; 20(5):166. PubMed ID: 30989447
[TBL] [Abstract][Full Text] [Related]
7. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
[TBL] [Abstract][Full Text] [Related]
8. Modified NAP test: A simple and Responsive Nitrosating Methodology for Risk Evaluation of NDSRIs.
Sharma N; Patel R; Bothara T; Jain S; Shah RP
J Pharm Sci; 2023 May; 112(5):1333-1340. PubMed ID: 36871894
[TBL] [Abstract][Full Text] [Related]
9. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control.
Tuesuwan B; Vongsutilers V
J Pharm Sci; 2021 Sep; 110(9):3118-3128. PubMed ID: 33989680
[TBL] [Abstract][Full Text] [Related]
10. Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s.
Li X; He X; Le Y; Guo X; Bryant MS; Atrakchi AH; McGovern TJ; Davis-Bruno KL; Keire DA; Heflich RH; Mei N
Arch Toxicol; 2022 Nov; 96(11):3077-3089. PubMed ID: 35882637
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous and trace level quantification of two potential genotoxic impurities in valsartan drug substance using UPLC-MS/MS.
Li S; Dong L; Tang K; Lan Z; Liu R; Wang Y; Wang R; Lin H
J Pharm Biomed Anal; 2022 Apr; 212():114630. PubMed ID: 35158183
[TBL] [Abstract][Full Text] [Related]
12. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
[TBL] [Abstract][Full Text] [Related]
13. Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA).
Bercu JP; Masuda-Herrera M; Johnson G; Czich A; Glowienke S; Kenyon M; Thomas R; Ponting DJ; White A; Cross K; Waechter F; Rodrigues MAC
Regul Toxicol Pharmacol; 2021 Jul; 123():104926. PubMed ID: 33862169
[TBL] [Abstract][Full Text] [Related]
14. Genotoxicity assessment of eight nitrosamines using 2D and 3D HepaRG cell models.
Seo JE; Yu JZ; Xu H; Li X; Atrakchi AH; McGovern TJ; Bruno KLD; Mei N; Heflich RH; Guo X
Arch Toxicol; 2023 Oct; 97(10):2785-2798. PubMed ID: 37486449
[TBL] [Abstract][Full Text] [Related]
15. Characterization of false positive, contaminant-driven mutagenicity in impurities associated with the sotorasib drug substance.
Coppi A; Davies R; Wegesser T; Ishida K; Karmel J; Han J; Aiello F; Xie Y; Corbett MT; Parsons AT; Monticello TM; Minocherhomji S
Regul Toxicol Pharmacol; 2022 Jun; 131():105162. PubMed ID: 35331777
[TBL] [Abstract][Full Text] [Related]
16. Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines.
Snodin DJ
Regul Toxicol Pharmacol; 2023 Jun; 141():105403. PubMed ID: 37116739
[TBL] [Abstract][Full Text] [Related]
17. Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.
Burns MJ; Ponting DJ; Foster RS; Thornton BP; Romero NE; Smith GF; Ashworth IW; Teasdale A; Simon S; Schlingemann J
J Pharm Sci; 2023 Dec; 112(12):3005-3011. PubMed ID: 37805074
[TBL] [Abstract][Full Text] [Related]
18. Ames test study designs for nitrosamine mutagenicity testing: qualitative and quantitative analysis of key assay parameters.
Thomas DN; Wills JW; Tracey H; Baldwin SJ; Burman M; Williams AN; Harte DSG; Buckley RA; Lynch AM
Mutagenesis; 2024 Mar; 39(2):78-95. PubMed ID: 38112628
[TBL] [Abstract][Full Text] [Related]
19. The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.
Schlingemann J; Burns MJ; Ponting DJ; Martins Avila C; Romero NE; Jaywant MA; Smith GF; Ashworth IW; Simon S; Saal C; Wilk A
J Pharm Sci; 2023 May; 112(5):1287-1304. PubMed ID: 36402198
[TBL] [Abstract][Full Text] [Related]
20. A new, rapid, stability-indicating UPLC method for separation and determination of impurities in amlodipine besylate, valsartan and hydrochlorothiazide in their combined tablet dosage form.
Vojta J; Jedlička A; Coufal P; Janečková L
J Pharm Biomed Anal; 2015 May; 109():36-44. PubMed ID: 25756663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]